Randomized Adaptive Platform Trial of Pathogen-Directed Anti-inflammatory Therapy in Severe Community-Acquired Pneumonia(Core Protocal)

NCT07152587 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

NOT_YET_RECRUITING

Status

1500

Enrollment

OTHER

Sponsor class

Conditions

Severe Community-acquired Pneumonia (sCAP)

Interventions

DRUG: Low dose steroids
DRUG: Moderate dose steroids
DRUG: Saline (0.9% NaCl)

Sponsor

Qingyuan Zhan